Intravitreal Aflibercept for Submacular Hemorrhage

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 20, 2019

Study Completion Date

January 20, 2019

Conditions
Exudative Age-related Macular Degeneration
Interventions
DRUG

Vascular endothelial growth factor trap-eye

Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.

Trial Locations (1)

150-034

Kim's Eye Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Kim's Eye Hospital

OTHER